The Pharma Letter
The biopharma industry is intensely competitive, and companies must go to great lengths to gain any commercial edge. However, it is also an industry that sees more failure than success. Leslie Orne, President & CEO of Trinity Life Sciences, provides an expert view in The Pharma Letter on how biopharma companies can make the best choices to achieve commercial success. Read Now…
MM+M Podcast
Trinity Life Science’s Monica Martin De Bustamante analyzes the Medicare-negotiated prices of the first 10 drugs under the Inflation Reduction Act. Listen Now…
Boston Business Journal
Check out Nancy Phelan’s profile in the Boston Business Journal. Read Now…
Pharmaceutical Executive
It’s clear that there is still work to be done with regard to diversity in clinical trials. Lisa Bailey, Managing Director and Head of DEI Strategy at Trinity Life Sciences, shares her insights with Pharmaceutical Executive on the lack of diversity in trials and how the industry can work to solve this problem. Read Now…
MedCity News
“While FDA approval has long been a singular prize, companies should also mine their assets for the strongest commercial opportunities. …the ability to take a drug to market is an important milestone, but it is not the entire picture. To truly move the needle, both clinically and commercially, biopharma companies must fine-tune their teams, approaches and incentives to produce unique and innovative products.”Read more from Leslie Orne’s new op-ed in MedCity News entitled, “Balancing Risk and Opportunities to Choose Winning…
Black Doctor
Trinity Life Sciences’ recent white paper on diversity in clinical trials was mentioned in an article published on Black Doctor. Read Now…
Fierce Biotech
Fierce Biotech mentioned Trinity Life Sciences’ recent white paper, Diversity in Clinical Trials: Life Sciences Initiatives and Challenges in Light of the FDA’s Latest Guidance, in their coverage of the updated FDA guidance. Read Now…
Fierce Biotech
Trinity Life Sciences’ recent white paper, Diversity in Clinical Trials: Life Sciences Initiatives and Challenges in Light of the FDA’s Latest Guidance, was featured in an article from Fierce Biotech highlighting how mistrust in the healthcare system is holding back trial diversity. Read Now…
HIT Consultant
Trinity’s Lisa Bailey, Ph.D., Managing Director & Head of DEI Strategy, was featured in an article by HIT Consultant. Learn more about the importance of diverse clinical trial populations in achieving equitable healthcare. Read Now…
AI Time Journal
Aparna Deshpande, PhD, Trinity’s Head of Insights & Analytics, was featured in an interview with AI Time Journal. Read the article to learn more about driving pharmaceutical innovation through Insights and Analytics. Read Now…
